Replication and persistence of Coxsackieviruses B3 in human fibroblasts

Tonew, M; Hartmann, Matthias; Schmidtke, Michaela; Stelzner, A.

doi:10.1016/s0934-8840(11)80801-7

Cited by 12 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It is possible that viruses hide in long living, immunologically privileged cells, including but not limited to, macrophages, muscles, myocardial cells, and neurones, [28][29][30][31][32][33][34][35][36][37] although these cells are unable to produce much live viruses, perhaps, in part, because of the pressure from local interferon and high concentrations of neutralising antibody-a form of cryptic infection. Viral antigen has been identified in tissues by virus specific monoclonal antibodies but positive staining did not allow the differentiation between membrane bound viral proteins and sequestered virions.…”

Section: Discussionmentioning

confidence: 99%

“…Lytic viruses can persist in vitro under conditions where only a small fraction of the total cells is infected at any one time. [28][29][30] CaCo-2 cells, an intestinal cell line, were shown to develop a persistent infection for up to 20 passages, as demonstrated by the detection of viral RNA and VP1 protein. 31 CVB can persistently infect endothelial cell cultures without producing overt cytopathic effects.…”

Section: In Vitro Viral Persistencementioning

confidence: 99%

See 1 more Smart Citation

The role of enterovirus in chronic fatigue syndrome

Chia

2005

J Clin Pathol

View full text Add to dashboard Cite

Two and a half decades after coining of the term chronic fatigue syndrome (CFS), the diagnosis of this illness is still symptom based and the aetiology remains elusive. Enteroviruses are well known causes of acute respiratory and gastrointestinal infections, with tropism for the central nervous system, muscles, and heart. Initial reports of chronic enteroviral infections causing debilitating symptoms in patients with CFS were met with skeptism, and had been largely forgotten for the past decade. Observations from in vitro experiments and from animal models clearly established a state of chronic persistence through the formation of double stranded RNA, similar to findings reported in muscle biopsies of patients with CFS. Recent evidence not only confirmed the earlier studies, but also clarified the pathogenic role of viral RNA through antiviral treatment. This review summarises the available experimental and clinical evidence that supports the role of enterovirus in chronic fatigue syndrome.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: In Vitro Viral Persistencementioning

confidence: 99%

The role of enterovirus in chronic fatigue syndrome

Chia

2005

J Clin Pathol

View full text Add to dashboard Cite

show abstract

“…Coxsackievirus B replication has been observed in different types of human cultured cells: myocardial fibroblasts, vascular endothelial cells, intestinal cells, thymocytes, fibroblasts, renal cells, and pancreas islets (18)(19)(20)(21)(22)(23)(24)(25).…”

Section: Introductionmentioning

confidence: 99%

Persistent Infection of a Carcinoma Thyroid Cell Line with Coxsackievirus B

Desailloud

Sané²,

Caloone³

et al. 2009

Thyroid

View full text Add to dashboard Cite

show abstract

“…The prototype of CVB3 was isolated about 70 years ago from a three-year-old child, named Nancy [ 99 ] and much of our knowledge about the mechanisms and progression of CVB3 disease in humans comes from animal studies in mice using “Nancy” and Nancy-related strains. In the last several decades, various CVB3 strains have been isolated from patients and some of them were subsequently adapted in vitro or in vivo to specific environments [ 68 , 91 , 100 , 101 , 102 ].…”

Section: Cvb3 Strains Their Oncolytic Activity and Treatment-related Side Effectsmentioning

confidence: 99%

Coxsackievirus B3—Its Potential as an Oncolytic Virus

Geisler

Hazini

Heimann

et al. 2021

Viruses

View full text Add to dashboard Cite

Oncolytic virotherapy represents one of the most advanced strategies to treat otherwise untreatable types of cancer. Despite encouraging developments in recent years, the limited fraction of patients responding to therapy has demonstrated the need to search for new suitable viruses. Coxsackievirus B3 (CVB3) is a promising novel candidate with particularly valuable features. Its entry receptor, the coxsackievirus and adenovirus receptor (CAR), and heparan sulfate, which is used for cellular entry by some CVB3 variants, are highly expressed on various cancer types. Consequently, CVB3 has broad anti-tumor activity, as shown in various xenograft and syngeneic mouse tumor models. In addition to direct tumor cell killing the virus induces a strong immune response against the tumor, which contributes to a substantial increase in the efficiency of the treatment. The toxicity of oncolytic CVB3 in healthy tissues is variable and depends on the virus strain. It can be abrogated by genetic engineering the virus with target sites of microRNAs. In this review, we present an overview of the current status of the development of CVB3 as an oncolytic virus and outline which steps still need to be accomplished to develop CVB3 as a therapeutic agent for clinical use in cancer treatment.

show abstract

Replication and persistence of Coxsackieviruses B3 in human fibroblasts

Cited by 12 publications

References 16 publications

The role of enterovirus in chronic fatigue syndrome

The role of enterovirus in chronic fatigue syndrome

Persistent Infection of a Carcinoma Thyroid Cell Line with Coxsackievirus B

Coxsackievirus B3—Its Potential as an Oncolytic Virus

Contact Info

Product

Resources

About